Endonovo Therapeutics (ENDV) Return on Capital Employed (2016 - 2023)
Endonovo Therapeutics has reported Return on Capital Employed over the past 10 years, most recently at 1.48% for Q3 2023.
- Quarterly results put Return on Capital Employed at 1.48% for Q3 2023, down 164.0% from a year ago — trailing twelve months through Sep 2023 was 1.48% (down 164.0% YoY), and the annual figure for FY2022 was 1.04%, down 118.0%.
- Return on Capital Employed for Q3 2023 was 1.48% at Endonovo Therapeutics, up from 1.53% in the prior quarter.
- Over the last five years, Return on Capital Employed for ENDV hit a ceiling of 0.34% in Q1 2020 and a floor of 1.9% in Q4 2020.
- Median Return on Capital Employed over the past 5 years was 0.14% (2021), compared with a mean of 0.51%.
- Biggest five-year swings in Return on Capital Employed: crashed -209bps in 2020 and later soared 204bps in 2021.
- Endonovo Therapeutics' Return on Capital Employed stood at 0.19% in 2019, then tumbled by -1112bps to 1.9% in 2020, then surged by 107bps to 0.14% in 2021, then tumbled by -824bps to 1.03% in 2022, then tumbled by -43bps to 1.48% in 2023.
- The last three reported values for Return on Capital Employed were 1.48% (Q3 2023), 1.53% (Q2 2023), and 1.36% (Q1 2023) per Business Quant data.